Breast Cancer
7
Companies
11
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Eli Lilly and Company
Abemaciclib
Roche Holding AG
trastuzumab (Herceptin®)
PUMA BIOTECHNOLOGY, INC.
Capecitabine
PUMA BIOTECHNOLOGY, INC.
vinorelbine
INTENSITY THERAPEUTICS, INC.
INT230-6
Arvinas, Inc.
Anastrozole
PUMA BIOTECHNOLOGY, INC.
Trastuzumab
Arvinas, Inc.
ARV-471
Marker Therapeutics, Inc.
Low dose FRα vaccine
MERCK
Lonafarnib
PUMA BIOTECHNOLOGY, INC.
Temsirolimus
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Abemaciclib | Phase 3 | — | — | — |
| RHHBY Roche Holding AG | trastuzumab (Herceptin®) | Phase 3 | — | — | — |
| PBYI PUMA BIOTECHNOLOGY, INC. | Capecitabine | Phase 2 | — | — | — |
| PBYI PUMA BIOTECHNOLOGY, INC. | vinorelbine | Phase 2 | — | — | — |
| INTS INTENSITY THERAPEUTICS, INC. | INT230-6 | Phase 2 | — | — | — |
| ARVN Arvinas, Inc. | Anastrozole | Phase 2 | — | — | — |
| PBYI PUMA BIOTECHNOLOGY, INC. | Trastuzumab | Phase 2 | — | — | — |
| ARVN Arvinas, Inc. | ARV-471 | Phase 2 | — | — | — |
| MRKR Marker Therapeutics, Inc. | Low dose FRα vaccine | Phase 2 | — | — | — |
| MRK MERCK | Lonafarnib | Phase 2 | — | — | — |
| PBYI PUMA BIOTECHNOLOGY, INC. | Temsirolimus | Phase 2 | — | — | — |
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.